Induction of bivalent immune responses by expression of dengue virus type 1 and type 2 antigens from a single complex adenoviral vector.
There are approximately 100 million new cases of dengue (DEN) virus infection each year. Infection can result in illness ranging from a mild fever to hemorrhaging, shock, or even death. There are four serotypes of dengue virus (DEN1-4), and immunity to one serotype does not cross protect from infection with other serotypes. Currently there are no approved vaccines for dengue fever. In this report, we describe the construction of a bivalent dengue virus vaccine using a complex recombinant adenovirus approach to express multiple genes of DEN1 and DEN2 serotypes. In vaccinated mice, this vector induced humoral immune responses against all four dengue serotypes as measured by enzyme-linked immunosorbent assay. However, the neutralizing antibody responses were specific for DEN1 and DEN2 serotypes. Expansion of this vaccine development platform towards the DEN3 and DEN4 serotypes can lead towards the development of an adenovirus-based tetravalent dengue vaccine.
Raja
Nicholas U
NU
Division of Biodefense Vaccines, GenPhar Incorporated, Mount Pleasant, South Carolina 29464, USA.
Holman
David H
DH
Wang
Danher
D
Raviprakash
Kanakatte
K
Juompan
Laure Y
LY
Deitz
Stephen B
SB
Luo
Min
M
Zhang
Jianghui
J
Porter
Kevin R
KR
Dong
John Y
JY
D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D000956:Antigens, Viral / Q000235:genetics* / Q000276:immunology*; D002460:Cell Line; D002522:Chlorocebus aethiops; D003715:Dengue / Q000276:immunology* / Q000821:virology*; D003716:Dengue Virus / Q000235:genetics* / Q000276:immunology*; D015870:Gene Expression; D006801:Humans; D051379:Mice; D014709:Vero Cells; D014765:Viral Vaccines / Q000235:genetics* / Q000276:immunology*
D000956:Antigens, Viral; D014765:Viral Vaccines